Keunwha teams up with BioDilivery Science

Published: 2010-06-07 06:56:00

Updated: 2010-06-07 06:56:00

Kunwha Pharmaceutical said on May 27 it has entered into a license and supply agreement with the U.S.-based BioDelivery Sciences International, Inc. for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in Korea. The agreement results in potential m...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK